Pharmacogenomic Knowledge Graph Augmentation for Graph Neural Network-Based Drug-Drug Interaction Prediction
📰 ArXiv cs.AI
Learn how to augment graph neural networks with pharmacogenomic knowledge graphs to improve drug-drug interaction prediction
Action Steps
- Build a pharmacogenomic knowledge graph using prior knowledge from Phar
- Integrate the knowledge graph with a graph neural network (GNN) architecture
- Train the GNN model using the augmented graph to predict drug-drug interactions
- Evaluate the model's performance using metrics such as accuracy and F1-score
- Compare the results with a baseline model without knowledge graph augmentation
Who Needs to Know This
Data scientists and researchers working on drug-drug interaction prediction can benefit from this knowledge to improve their model's performance
Key Insight
💡 Augmenting graph neural networks with pharmacogenomic knowledge graphs can improve drug-drug interaction prediction performance
Share This
Boost drug-drug interaction prediction with pharmacogenomic knowledge graphs #GNN #DDI #Pharmacogenomics
Key Takeaways
Learn how to augment graph neural networks with pharmacogenomic knowledge graphs to improve drug-drug interaction prediction
Full Article
Title: Pharmacogenomic Knowledge Graph Augmentation for Graph Neural Network-Based Drug-Drug Interaction Prediction
Abstract:
arXiv:2606.07698v1 Announce Type: cross Abstract: Graph neural networks (GNNs) applied to drug-drug interaction (DDI) prediction rely exclusively on molecular structure encoded as SMILES-derived graphs. Prior work in this series demonstrated that model performance is bounded by the structural information content of training labels -- an Information Ceiling -- that architectural refinements alone cannot overcome. The present study investigates whether pharmacogenomic prior knowledge from the Phar
Abstract:
arXiv:2606.07698v1 Announce Type: cross Abstract: Graph neural networks (GNNs) applied to drug-drug interaction (DDI) prediction rely exclusively on molecular structure encoded as SMILES-derived graphs. Prior work in this series demonstrated that model performance is bounded by the structural information content of training labels -- an Information Ceiling -- that architectural refinements alone cannot overcome. The present study investigates whether pharmacogenomic prior knowledge from the Phar
DeepCamp AI